Richard Gregg

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text

Medicine, Oncology, Cancer Pharmacology +11

Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity.

Richard Gregg, J. Matshela Molepo, V J Monpetit et al. · Journal of Clinical Oncology · 1992 · 360 citations

Pharmacy, Pharmacology, Toxicology +16

Multitargeted Antifolate LY231514 as First-Line Chemotherapy for Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II Study

James J. Rusthoven, Elizabeth A. Eisenhauer, Charles Butts et al. · Journal of Clinical Oncology · 1999 · 218 citations

Medicine, Oncology, Pharmacology +14

Phase II Study of Vandetanib or Placebo in Small-Cell Lung Cancer Patients After Complete or Partial Response to Induction Chemotherapy With or Without Radiation Therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20

Andrew Arnold, Lesley Seymour, Michael Smylie et al. · Journal of Clinical Oncology · 2007 · 196 citations · Full text

Medicine, Oncology, Pharmacology +17

Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC)

Yvon Cormier, E. Eisenhauer, A. Muldal et al. · Annals of Oncology · 1994 · 147 citations

Medicine, Oncology, Pharmacology +10